Lab Sciences
Top stories summarized by our editors
11/8/2018

A study indicated similar efficacy profiles for daclatasvir plus sofosbuvir plus ribavirin and velpatasvir/sofosbuvir plus ribavirin in patients with hepatitis C virus genotypes 2 and 3. The study appears in the Journal of Hepatology.

Full Story:
MD Magazine online
More Summaries:
ribavirin
11/8/2018

Bristol-Myers Squibb's Empliciti, or elotuzumab, in combination with Celgene's Pomalyst, or pomalidomide, and dexamethasone, was approved by the FDA under priority review to treat adult patients with multiple myeloma who have received two or more prior lines of treatment.

Full Story:
Seeking Alpha
11/8/2018

Rocket Pharmaceuticals announced that its investigational new drug application for its gene therapy candidate RP-L102, indicated for the treatment of Fanconi anemia, has been approved by the FDA. The study is scheduled to launch next quarter, and Rocket will collaborate with regulatory authorities in the second half of 2019 on a registration process.

Full Story:
Seeking Alpha
11/7/2018

Yellow fever vaccines totaling 1.45 million doses were released from the World Health Organization's emergency stockpile, prompted by the deaths of 10 people in Ethiopia from the mosquito-borne disease. "This outbreak is of concern since the population of Ethiopia is highly susceptible to yellow fever due to absence of recent exposure and lack of large-scale immunization," according to a WHO report.

Full Story:
Reuters
11/6/2018

Patients with sickle cell disease who were treated with Novartis' crizanlizumab noted a reduction in pain when experiencing vaso-occlusive crisis, based on data from a midstage trial evaluating the drug's safety and efficacy. Details of the research were published in the American Journal of Hematology.

Full Story:
Rare Disease Report
More Summaries:
Novartis, vaso-occlusive crisis
11/6/2018

Performing monthly internal audits is helping Ohio-based MetroHealth, a countywide health care system, improve point-of-care testing system across all of its sites, writes Vikram Palamalai, director of POCT at MetroHealth Medical Center. "POCT ... at MetroHealth continues to expand rapidly and is offered more and more at non-traditional sites, bringing new challenges to ensuring compliance. Audits have enabled us to identify specific risks and problem sites despite this growth," Palamalai writes.

11/5/2018

Researchers at the University of Southern California have identified 16 cytokines whose presence in maternal blood during pregnancy was linked with symptomatic cases of neonatal Zika virus infection, according to a study in JCI Insight. Researchers said the study could lead to the development of screening tests.

11/5/2018

Uganda is launching a preventive Ebola virus vaccination campaign for about 2,100 health workers near the border with the Democratic Republic of Congo. Two new Ebola cases in the DRC city of Beni were reported Friday, bringing the total for the current outbreak to 287.

More Summaries:
Ebola
11/5/2018

A study by the NIH and Brazil's Sao Paulo-Minas Gerais Tropical Medicine Research Center found that benznidazole treatment for chronic Chagas' disease was associated with decreased mortality, parasite counts and cardiomyopathy markers. The study was based on data for about 1,800 patients.

More Summaries:
NIH, benznidazole, cardiomyopathy
11/2/2018

A Phase I/IIa study in the British Journal of Haematology found the compound DTP3, an inhibitor of the protein GADD45b and the enzyme MKK7, was associated with a halt of cancer progression in two of three patients. No complications were reported, and the patients completed their 28-day regimens.

Full Story:
Myeloma Research News
More Summaries:
multiple myeloma